Compare PROF & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PROF | RNAC |
|---|---|---|
| Founded | N/A | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.8M | 238.9M |
| IPO Year | 2017 | 2016 |
| Metric | PROF | RNAC |
|---|---|---|
| Price | $6.80 | $10.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $12.00 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 139.4K | 120.1K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.89 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,098,000.00 | $2,797,000.00 |
| Revenue This Year | $92.40 | N/A |
| Revenue Next Year | $64.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 50.73 | N/A |
| 52 Week Low | $3.92 | $5.60 |
| 52 Week High | $8.95 | $11.39 |
| Indicator | PROF | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 44.69 | 68.94 |
| Support Level | $6.24 | $5.88 |
| Resistance Level | $7.03 | $10.98 |
| Average True Range (ATR) | 0.45 | 0.56 |
| MACD | -0.09 | 0.23 |
| Stochastic Oscillator | 14.57 | 77.42 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.